| Jun'19 | Jun'18 | Jun'17 | Jun'16 | Dec'14 | Dec'13 | Mar'13 | Dec'12 | Mar'12 | Dec'11 |
|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||
NET LOSS | |||||||||
-18,016 | -6,311 | -2,142 | -1,735 | -2,370 | -2,147 | -37 | -2,427 | -29 | -34 |
ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES: | |||||||||
Change in Consideration of Contingent Consideration Liability | |||||||||
- | - | 0 | - | - | - | - | - | - | - |
Depreciation and amortization | |||||||||
71 | 18 | 14 | 27 | 45 | 38 | - | 56 | - | - |
Change in contingent consideration liability | |||||||||
7,073 | 1,375 | - | - | - | - | - | - | - | - |
Non-cash stock-based compensation expense | |||||||||
2,164 | 281 | - | - | - | - | - | - | - | - |
Non-Cash and Stock-Based Compensation Expense | |||||||||
- | - | 982 | 0 | - | - | - | - | - | - |
Accrued Interest on Notes Payable - Related Party | |||||||||
- | - | 2 | 2 | - | 0 | - | - | - | - |
Accrued Interest on Notes Receivable | |||||||||
- | - | 0 | - | - | - | - | - | - | - |
Loss on Forgiveness on Note Receivable | |||||||||
- | 457 | 0 | - | - | - | - | - | - | - |
Gain on forgiveness of debt, related party | |||||||||
- | 87 | 0 | - | - | - | - | - | - | - |
Accretion of discount on notes payable | |||||||||
- | 11 | 20 | 0 | - | - | - | - | - | - |
(Gain)/Loss on sale of equipment | |||||||||
- | - | - | - | - | - | - | 15 | - | - |
(Gain)/Loss on sale of subsidiary | |||||||||
- | - | - | - | - | 0 | - | 0 | - | - |
Accretion of discount on bond payable | |||||||||
- | - | - | - | - | 502 | - | 461 | - | - |
(Gain)/Loss on derivative liability | |||||||||
- | - | - | - | - | 175 | - | 142 | - | - |
CHANGES IN ASSETS AND LIABILITIES: | |||||||||
(Increase) Decrease in Other Receivables | |||||||||
- | - | - | - | -17 | -56 | - | - | - | - |
Other Receivables | |||||||||
- | - | - | - | - | - | - | 17 | - | - |
Other receivables | |||||||||
-119 | -108 | -471 | 263 | - | - | - | - | - | - |
Professional fees paid by related party on behalf of the Company | |||||||||
- | - | - | - | - | - | 0 | - | 5 | 13 |
(Decrease) Increase in accounts payable and accrued expenses | |||||||||
- | - | - | - | - | - | 7 | - | 0 | - |
Prepaid expenses/deposits | |||||||||
160 | 138 | 19 | 13 | - | - | - | - | - | - |
(Increase) Decrease in Prepaid Expenses/Deposits | |||||||||
- | - | - | - | -22 | -4 | - | 8 | - | - |
Accounts payable | |||||||||
-29 | 119 | -652 | 574 | 162 | -2 | - | 450 | - | 0 |
Accrued interest on notes receivable | |||||||||
- | 10 | - | - | - | - | - | - | - | - |
Accounts payable-non-trade | |||||||||
- | - | 137 | -268 | 212 | 0 | - | - | - | - |
Accrued expenses | |||||||||
269 | -161 | 9 | 203 | -124 | -406 | - | 710 | - | - |
NET CASH USED IN OPERATINGACTIVITIES | |||||||||
-8,507 | -4,338 | -1,177 | - | -2,034 | -2,130 | -30 | -933 | -24 | -20 |
Total Adjustments | |||||||||
- | - | 965 | 262 | 336 | 16 | - | 1,494 | - | - |
NET CASH USED IN OPERATING ACTIVITIES | |||||||||
- | - | - | -1,472 | - | - | - | - | - | - |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||
Net cash used for acquisition of Enochian BioPharma Inc. | |||||||||
- | 294 | 0 | - | - | - | - | - | - | - |
Net decrease (increase) in cash held in escrow | |||||||||
- | - | - | 1,052 | -1,952 | -77 | - | - | - | - |
Notes receivable | |||||||||
- | 250 | 196 | 0 | - | - | - | - | - | - |
Proceed from sale of subsidiary | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Purchase of property and equipment | |||||||||
716 | 30 | - | - | - | - | - | - | - | - |
Proceeds from stock sales | |||||||||
- | - | - | - | 7,377 | 0 | - | - | - | - |
Payment of stock offering costs | |||||||||
- | - | - | - | 89 | 67 | - | 0 | - | - |
Payments on Notes Payable - Related Party | |||||||||
- | - | - | - | 1,432 | - | - | - | - | - |
Proceeds from sale of subsidiary | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Proceeds from sale of equipment | |||||||||
- | - | - | - | - | - | - | 15 | - | - |
Net (Increase) in Cash held in Escrow | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Purchase of intangible assets | |||||||||
- | - | - | - | - | 27 | - | 99 | - | - |
Amounts received from related parties to satisfy loans receivable | |||||||||
- | - | - | - | - | - | 0 | - | -13 | 13 |
NET CASH USED IN INVESTING ACTIVITIES | |||||||||
-716 | -575 | -196 | - | -1,952 | -105 | 0 | -84 | -13 | -13 |
NET CASH USED BY INVESTING ACTIVITIES | |||||||||
- | - | - | 1,052 | - | - | - | - | - | - |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||
Proceeds from notes payable - related party | |||||||||
- | - | 1,582 | 0 | - | -218 | 16 | - | 8 | - |
Proceeds from convertible notes payable - long-term | |||||||||
- | - | 413 | 0 | - | - | - | - | - | - |
Proceeds from notes payable - long-term | |||||||||
- | - | - | - | 814 | 2,754 | 20 | 856 | 5 | - |
Payments on Notes Payable - Related Party | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Proceed from the issuance of common stock | |||||||||
- | 16,712 | 3,510 | 0 | - | - | 0 | - | 25 | 25 |
Proceeds from exercise of warrants | |||||||||
6,020 | - | - | - | - | - | - | - | - | - |
NET CASH PROVIDED BY (USED BY) FINANCING ACTIVITIES | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
NET CASH PROVIDED BY FINANCING ACTIVITIES | |||||||||
6,020 | 16,712 | 5,506 | - | 6,669 | 2,469 | 36 | 856 | 38 | 33 |
Loss on currency translation | |||||||||
-114 | -139 | -214 | 21 | 306 | -219 | - | -85 | - | - |
NET CHANGE IN CASH | |||||||||
-3,318 | 11,659 | 3,918 | -397 | 2,990 | 14 | 6 | -246 | 0 | - |
NET INCREASE IN CASH | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | |||||||||
Interest | |||||||||
0 | 143 | - | - | - | - | - | - | - | - |
Interest | |||||||||
- | - | 21 | 0 | 82 | 12 | - | 0 | - | - |
Income Taxes | |||||||||
- | - | 64 | 0 | 0 | - | - | 0 | - | - |
Income Taxes | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Non-cash investing and financing activities: | |||||||||
Contingent Shares issued in connection with Acquisition Agreement | |||||||||
24,297 | - | - | - | - | - | - | - | - | - |
Compensation for the issuance of warrants for consulting | |||||||||
- | - | 115 | 0 | - | - | - | - | - | - |
Stock options to the Board | |||||||||
- | - | 626 | 0 | - | - | - | - | - | - |
Convertible Notes payable converted to 258,544 Common Shares | |||||||||
- | 401 | 0 | - | - | - | - | - | - | - |
Compensation for the issuance of stock for consulting services | |||||||||
40 | 105 | 240 | 0 | - | - | - | - | - | - |
Discount for imputed interest on non-interest bearing Convertible Notes Payable | |||||||||
- | -9 | 14 | 0 | - | - | - | - | - | - |
Issuance of stock for compensation | |||||||||
- | 112 | - | - | - | - | - | - | - | - |
Compensation for the issuance of stock to officers and directors | |||||||||
2,124 | 63 | - | - | - | - | - | - | - | - |
Beneficial Conversion Feature of Convertible Notes Payable | |||||||||
- | - | 17 | 0 | - | - | - | - | - | - |
Amortization of discount on Convertible Notes Payable | |||||||||
- | - | 20 | 0 | - | - | - | - | - | - |
Common stock issued and contingent consideration shares of Common Stock to acquire Enochian BioPharma, Inc. | |||||||||
- | 166,469 | - | - | - | - | - | - | - | - |
Accretion of discount on bond payable | |||||||||
- | - | - | - | - | 502 | - | 461 | - | - |
Change in fair market value of derivative liability | |||||||||
- | - | - | - | - | -175 | - | 142 | - | - |
Professional fees paid by related party on behalf of the Company | |||||||||
- | - | - | - | - | - | 0 | - | 5 | 13 |
Professional fees paid by related party on behalf of the Company | |||||||||
- | - | - | - | - | - | - | - | - | 13 |
Common stock subscribed | |||||||||
- | - | - | - | - | - | 0 | - | 0 | 25 |
Common Stock issued and contingent consideration shares of Common Stock to acquire Enochian Biopharma | |||||||||
- | - | 0 | - | - | - | - | - | - | - |